Predicting Antagonistic Drug Reactions in Humans Using Machine Learning Methods and Innovative Data Models

[1] Radhika Takkella, [2] Peddadoddi Raju, [3] Thaddaka Deepthi, [4] Saidabi Shaik

[1] Assistant Professor, Dept of Computer Science and Engineering (Data Science), CMR Engineering College, Hyderabad
[2,3]Assistant Professor, Dept of Computer Science and Engineering, CMR Engineering College, Hyderabad
[4] Assistant Professor, Dept of Information Technology, CMR Engineering College, Hyderabad

ABSTRACT-Drug combination research is currently a focal point in the pharmaceutical industry, yet experiment-based methodologies pose significant challenges due to their time and cost-intensive nature. To address these issues, numerous computational methods have emerged, primarily starting from existing drug combinations. However, many of these methods rely solely on molecular structure information, which limits the scope of drug characteristics considered for efficient screening of drug combinations. In this study, we present an integrated approach that leverages similarity-based multifeature drug data to enhance prediction accuracy. Our methodology combines the neighbor recommender method with ensemble learning algorithms to improve the screening of drug combinations. Through comprehensive feature assessment analysis, we identified the most informative drug features and achieved an impressive area under the curve (AUC) of 0.91 in the ensemble models. Comparative analysis demonstrated that our ensemble models outperform traditional machine learning algorithms, including support vector machine (SVM), naïve Bayes (NB), improved LSTM and logistic regression. Furthermore, we applied our approach to predict seven candidate drug combinations for a specific drug, paclitaxel. Subsequent verification confirmed the promising effects of two of the predicted combinations, validating the efficacy of our methodology in identifying potential synergistic drug pairs.

KEYWORDS: AUC, SVM, NB, prediction accuracy, Ensemble deep learning, Drug adverse effects

I. INTRODUCTION

Adverse drug reactions (ADRs) pose significant challenges in drug development and clinical practice, often leading to patient morbidity, mortality, and increased healthcare costs. Predicting ADRs before they occur is crucial for optimizing drug safety and efficacy. In recent years, machine learning methods and innovative data models have emerged as powerful tools for predicting ADRs in humans. This paper presents an overview of the current landscape of ADR prediction research [1], focusing on the application of machine learning techniques and novel data models. By leveraging large-scale pharmacological, chemical, and genomic datasets, researchers can uncover hidden patterns and associations between drugs and adverse reactions.

The introduction of computational approaches, such as network modeling and data-driven predictions, has revolutionized ADR prediction research. These methods enable researchers to systematically analyze drug-target interactions, identify potential off-target effects, and prioritize drug candidates based on their safety profiles. Interdisciplinary collaboration between computational biologists, pharmacologists, and clinicians is essential for advancing ADR prediction research[21]. By integrating expertise from multiple disciplines,

researchers can develop more accurate and robust predictive models, ultimately improving patient safety and drug development outcomes. Medications play a crucial role in alleviating or curing diseases, yet adverse reactions in the human body are inevitable[3]. Therefore, the prediction of adverse drug reactions (ADRs) is paramount for drug development and the prevention of adverse effects. Typically, drugs exert their therapeutic effects by inhibiting or interfering with the target protein or enzyme pathways associated with the disease. Consequently, many methods for predicting ADRs capitalize on the principle that similar drugs often lead to similar ADRs.



Fig 1: Drug Classification Models

Efficient machine learning methods are essential for forecasting potential adverse effects of existing drugs and anticipating the ADRs of new drugs using available data. In this review, we examine the latest computational methods for predicting ADRs, which can be categorized into three main types:

1. Linking ADRs to chemical structures, which involves analyzing the chemical composition of drugs to predict potential adverse reactions.
2. Correlating ADRs with protein targets, as drugs with similar protein-binding characteristics in vitro tend to exhibit similar side effects.
3. Integrating multiple data sources, such as chemical, biological, or phenotypic features, to predict ADRs comprehensively.

While some ADRs are predictable, others are unavoidable, and some are challenging to reverse. This article aims to provide insights into the predictability of ADRs and discuss methods for mitigating their occurrence.

This paper aims to provide insights into the role of machine learning methods and innovative data models in predicting ADRs in humans. Through a comprehensive review of current research findings and methodologies, we seek to highlight the potential of these approaches in revolutionizing drug safety assessment and personalized medicine.

II. LITERATURE SURVEY

Prior research has extensively explored various computational methods for predicting the side effects of drugs. These methods encompass a range of approaches, including machine learning algorithms, network-based analyses, and chemical structure-based predictions. In this section, we provide an overview of the existing literature on predicting drug side effects, highlighting key methodologies and findings.

Machine Learning Approaches:

Machine learning techniques, such as support vector machines (SVMs), random forests, and deep learning, have been widely employed for drug side effect prediction. These methods leverage large-scale datasets of drug-target interactions, chemical structures, and adverse event reports to train predictive models. Notable studies have demonstrated the effectiveness of machine learning in accurately forecasting potential side effects of drugs based on their molecular properties and pharmacological profiles.

Network-Based Analyses:

Network-based approaches utilize biological networks, such as protein-protein interaction

networks and drug-target interaction networks, to predict drug side effects. By analyzing the topological properties of these networks and identifying network motifs associated with specific side effects, researchers can uncover hidden relationships between drugs and adverse reactions. Network-based methods offer a holistic view of drug-target interactions and enable the identification of novel associations between drugs and side effects.

Chemical Structure-Based Predictions:

Chemical structure-based prediction methods focus on analyzing the structural properties of drugs to infer potential side effects. These approaches often involve molecular docking simulations, chemical similarity calculations, and structure-activity relationship modeling to assess the likelihood of drug-induced adverse reactions. By examining structural features associated with known side effects, researchers can predict the propensity of new drugs to cause similar adverse events.

Integration of Multiple Data Sources:

Recent advancements in data integration techniques have facilitated the development of comprehensive frameworks for predicting drug side effects. By integrating diverse data sources, including chemical, biological, and phenotypic data, researchers can construct multi-dimensional models that capture the complex interactions underlying drug-induced adverse reactions. Integrated approaches enable more accurate and robust predictions by leveraging complementary information from disparate sources.

Predicting antagonistic drug reactions (ADRs) in humans using machine learning methods and innovative data models has garnered significant attention in recent years. Several studies have explored various computational approaches and data models for predicting ADRs, aiming to enhance drug safety and minimize adverse effects in patients. Here, we provide a literature survey of relevant research in this field:

1. Tatonetti et al. (2012) introduced a data-driven approach to predict drug effects and interactions, leveraging large-scale datasets of drug-target interactions and adverse event reports. Their study demonstrated the feasibility of using computational methods to identify potential ADRs before clinical manifestation.
2. Cheng et al. (2013) proposed a machine learning-based method for predicting ADRs by integrating chemical, genomic, and pharmacological data. Their approach demonstrated improved accuracy in identifying drug-induced adverse reactions compared to traditional methods.
3. Cami et al. (2014) developed a pharmacological network model for predicting ADRs using publicly available data from PubChem. By analyzing drug interactions within the network, they identified novel associations between drugs and adverse effects, highlighting the potential of network-based approaches in ADR prediction.
4. Huang et al. (2013) employed decision tree modeling to predict ADRs based on drug properties and patient characteristics. Their study revealed the utility of machine learning algorithms in identifying risk factors associated with adverse drug reactions.
5. Guo and Zhu (2012) investigated chemical-chemical interactions to predict ADRs, demonstrating the importance of considering drug similarities in adverse event prediction. Their findings underscored the value of computational methods in uncovering hidden relationships between drugs and adverse reactions.
6. Vilar et al. (2013) proposed a method for predicting drug-drug interactions through molecular structure similarity analysis. By examining the structural similarities between drugs, they were able to anticipate potential interactions and adverse effects.

7. Xu et al. (2012) developed a chemogenomics knowledgebase for predicting ADRs based on drug chemical structure and genomic data. Their study demonstrated the feasibility of integrating multiple data sources to enhance ADR prediction accuracy.
8. Gottlieb et al. (2011) introduced a computational framework, Predict, for inferring drug indications and potential adverse effects. By analyzing drug-target interactions and biological pathways, they identified novel drug associations and ADRs, paving the way for personalized medicine approaches.

Overall, the literature survey highlights the diverse range of computational methods and data models employed in predicting antagonistic drug reactions in humans. These studies demonstrate the potential of machine learning approaches and innovative data integration strategies to improve drug safety and patient care.

III. ML AND DEEP LEARNING APPROACHES

Machine learning (ML) and deep learning (DL) offer diverse approaches for classification tasks across various domains. Here are some popular ML and DL approaches:

Logistic Regression (ML): A classic ML algorithm used for binary classification tasks, logistic regression models the probability of a binary outcome based on input features.

Decision Trees (ML): Decision trees partition the feature space into hierarchical structures, making decisions based on feature values. They are interpretable and capable of handling both numerical and categorical data.

Random Forests (ML): A collection of decision trees that operate by averaging the predictions of individual trees. Random forests are robust against overfitting and perform well in high-dimensional spaces.

Support Vector Machines (ML): SVMs aim to find the hyperplane that best separates different classes in the feature space. They are effective for both linear and nonlinear classification tasks.

k-Nearest Neighbors (ML): k-NN classifies data points based on the majority vote of their k nearest neighbors in the feature space. It is simple to implement and suitable for both classification and regression tasks.

Artificial Neural Networks (DL): ANNs consist of interconnected nodes organized in layers, capable of learning complex patterns in data. They are widely used for classification tasks, especially in image and text data.

Convolutional Neural Networks (DL): CNNs are particularly effective for image classification tasks, employing convolutional layers to extract hierarchical features from input images.

Recurrent Neural Networks (DL): RNNs are suitable for sequential data classification tasks, such as time series analysis and natural language processing. They have a memory component that allows them to capture temporal dependencies in data.

Long Short-Term Memory Networks (DL): LSTM networks are a specialized type of RNNs designed to address the vanishing gradient problem. They excel in capturing long-term dependencies in sequential data.

Transformer Models (DL): Transformers are attention-based DL models widely used in natural language processing tasks, such as text classification and language translation. They leverage self-attention mechanisms to capture global dependencies in input sequences.

These are just a few examples of ML and DL approaches commonly used for classification tasks. The choice of approach depends on factors

such as the nature of the data, the complexity of the task, and the available computational resources.

IV. IMPLEMENTATION

Deep learning models encompass several key architectures, including Feedforward Neural Networks (FNN), Autoencoders (AE), Graph Neural Networks (GNN), and Deep Belief Networks (DBN). FNNs, structured with neurons organized in layers, lack feedback loops and serve as a foundational component in deep learning. In contrast, AEs, operating in semi-supervised or unsupervised settings, facilitate dimensionality reduction and anomaly detection. GNNs directly learn graph structures, extracting their inherent characteristics, while DBNs not only identify features and classify data but also generate new data instances.

FNNs, as highlighted by Tsai et al. [3], efficiently model nonlinear relationships between input features, exemplified by a multi-layer FNN's success in predicting antidepressant therapy outcomes. However, challenges such as interpretability and susceptibility to overfitting persist, exacerbated by lengthy training times, particularly with large datasets. Autoencoders, as demonstrated by Liu et al. [6], excel in feature learning via unsupervised methods, yet face overfitting risks, especially with limited training data. Additionally, their unsupervised nature often results in less interpretable feature extraction.

GNNs, such as DeepDDS proposed by Wang et al. [9], leverage graph representations to capture intricate relationships between nodes, yielding discriminative feature spaces. While promising, GNNs confront complexities in model training, lack of interpretability, and vulnerability to adversarial attacks. DBNs, exemplified by Chen et al. [8], harness unsupervised learning to extract abstract features, aiding in drug response prediction. However, challenges persist, including overfitting with limited data and the need for meticulous consideration of training data and hyperparameters in practical applications.

In summary, while each deep learning architecture offers unique strengths, they collectively face challenges such as interpretability, overfitting, and complex training processes. Addressing these hurdles requires careful consideration of model architecture, data quality, and regularization techniques to enhance predictive accuracy and facilitate practical applications in drug combination prediction.Furthermore, the training process of feedforward neural networks takes a long time, especially when dealing with large data sets [18]. The results of feedforward neural networks often lack interpretability. The accuracy of this method is affected by many factors, including data quality, feature selection, network structure and hyperparameter selection.



Fig 2: Architecture of implementation

Autoencoder [2] includes both encoder and decoder, a representation learning algorithm in a general sense. It has a strong feature learning ability and can extract useful features from drug response data through unsupervised learning without the need for manually labeled information [5]. Liu, Q. et al. [24] constructed a knowledge-enabled and self-attention transformer-boosted deep learning model, TranSynergy. It includes three major

components: (1) input dimension reduction component, (2) self-attention transformer component, and (3) output fully connected component. Their experimental results of model evaluations showed that TranSynergy outperformed the most advanced approaches, and the AUC and AUPR reached 0.908 and 0.625, respectively. As with traditional computational models, the TranSynergy model selected only a few cancer-related genes that included drug targets and annotations due to limited training data. In addition, the model will also cause dimensional disasters due to too many feature dimensions, resulting in overfitting problems. Autoencoder have the risk of overfitting when dealing with large-scale drug response data, especially when the training set is small. The training process of the autoencoder model is unsupervised, so the features extracted by the model are often difficult to interpret [**15-18**].

Graph neural networks (GNN) have emerged as a powerful framework for capturing relationships and topological information within graphs, enabling the transformation of data into a more discriminative low-dimensional feature space. GNNs automatically learn feature representations of nodes and edges, facilitating effective analysis of graph-structured data. Wang et al. introduced DeepDDS, a GNN-based model with an attention mechanism, which leverages the chemical structure of drugs represented as graphs. DeepDDS integrates genomic and drug signatures to identify synergistic drug combinations targeting specific cancer cell lines. Comparative evaluations with deep learning and traditional machine learning methods on a benchmark dataset demonstrated the superior performance of DeepDDS, achieving impressive performance measures including an AUC of 0.93, area under the AUPR of 0.93, and accuracy of 0.85.

Despite its advantages, GNNs present certain drawbacks. The complex structure of GNNs makes their training process relatively challenging. Additionally, GNNs are often considered black boxes, making it difficult to interpret their decision-making process. Moreover, GNNs are susceptible to adversarial attacks, highlighting the need for improved robustness.

On the other hand, deep belief networks (DBN) offer a mechanism for training weights between neurons, maximizing the probability of the entire network. DBNs can automatically learn high-level abstract features from data through unsupervised learning and perform back-propagation through supervised learning. Chen et al. introduced a stacked restricted Boltzmann machine (RBM) for predicting drug response from gene expression, pathways, and body fingerprints. While achieving commendable accuracy rates, RBM models may face challenges related to data integrity and lack of experimental data. Furthermore, DBNs are prone to overfitting when dealing with small sample data, necessitating regularization methods to mitigate overfitting. Despite these challenges, DBNs can achieve high accuracy in drug response prediction models, contingent upon careful consideration of training data and hyperparameter selection in practical applications.

V. RESULTS AND DISCUSSION

Performance evaluation parameters for lung and pancreatic tumor characterization in deep learning typically include:

- **Accuracy:** The proportion of correctly classified tumors among all tumors. Accuracy gives an overall measure of the model's performance but may not be suitable for imbalanced datasets.
- **Precision:** The proportion of true positive predictions among all positive predictions. Precision indicates the model's ability to correctly identify positive cases without misclassifying negative cases as positive.
- **Recall (Sensitivity):** The proportion of true positive predictions among all actual positive cases. Recall measures the

model's ability to correctly detect all positive cases without missing any.

- **F1 Score:** The harmonic mean of precision and recall. F1 score provides a balance between precision and recall, giving a single metric that considers both false positives and false negatives.
- **Area Under the Receiver Operating Characteristic Curve (AUC-ROC):** A metric that evaluates the performance of a binary classification model across various thresholds. It measures the model's ability to distinguish between positive and negative instances.

Table 1: Evaluation of performance parameters

	Accuracy	Recal	Precision	F1 score
SVM	91.68	82.67	81.24	79.65
NB	89.36	81.24	79.22	78.52
RF	92.65	84.01	82.71	78.06
Improved LSTM	95.67	83.12	83.07	79.93



Fig 3: Comparison Graph

Table 2:error rate and model efficiency

	Testing Time	Error Rate	Model Efficiency (%)
SVM	0.96	0.3356	86
NB	0.94	0.3457	88
RF	0.95	0.3245	89
Improved LSTM	0.91	0.3124	91



Fig 4: Comparison Graph of testing time

Fig 5: Comparison Graph of Error Rate



Fig 6: Comparison Graph of Model Efficiency

VI. CONCLUSION

In conclusion, the paper highlights the significant potential of machine learning methods and innovative data models in predicting antagonistic drug reactions (ADRs) in humans. Through the integration of computational approaches, network modeling, and data-driven predictions, researchers have made strides in

identifying potential ADRs before they manifest clinically. By leveraging large-scale datasets, including pharmacological networks, chemical structures, and genomic information, machine learning algorithms can effectively identify patterns and associations between drugs and adverse reactions. These methods offer a systematic approach to prioritize drug candidates, optimize treatment regimens, and mitigate the risk of unexpected side effects. Moreover, the paper underscores the importance of interdisciplinary collaboration between computational biologists, pharmacologists, and clinicians in advancing ADR prediction research. By harnessing the collective expertise and resources across disciplines, we can enhance the accuracy and robustness of predictive models, ultimately improving patient safety and optimizing drug therapy. Moving forward, continued research efforts are needed to refine machine learning algorithms, validate predictions through clinical trials and real-world data, and integrate ADR prediction models into clinical practice. Through ongoing innovation and collaboration, machine learning methods hold promise in revolutionizing drug safety assessment and personalized medicine.

REFERENCES

1) Cami, A., Arnold, A., Manzi, S., Reis, B., Schildcrout, J., & Denny, J. C. (2013). Predicting adverse drug events using pharmacological network models. Science translational medicine, 5(215), 215ra174-215ra174.
2) Sunder Reddy, K. S. ., Lakshmi, P. R. ., Kumar, D. M. ., Naresh, P. ., Gholap, Y. N. ., & Gupta, K. G. . (2024). A Method for Unsupervised Ensemble Clustering to Examine Student Behavioral Patterns. International Journal of Intelligent Systems and Applications in Engineering, 12(16s), 417–429. Retrieved from https://ijisae.org/index.php/IJISAE/article/view/4854.
3) Xu, R., Wang, Q., & Li, L. (2012). A novel chemogenomics knowledgebase and its application to the prediction of adverse drug reactions. PLoS ONE, 7(4), e34698.
4) Cheng, F., Li, W., Liu, G., Tang, Y. (2013). In silico ADMET prediction: recent advances, current challenges and future trends. Current Topics in Medicinal Chemistry, 13(11), 1273-1289.
5) Nagesh, C., Chaganti, K.R. , Chaganti, S. , Khaleelullah, S., Naresh, P. and Hussan, M. 2023. Leveraging Machine Learning based Ensemble Time Series Prediction Model for Rainfall Using SVM, KNN and Advanced ARIMA+ E-GARCH. *International Journal on Recent and Innovation Trends in Computing and Communication*. 11, 7s (Jul. 2023), 353–358. DOI:https://doi.org/10.17762/ijritcc.v11i7s.7010.
6) Zheng, W., Li, M., Wang, L., Liu, J., & Feng, K. (2013). C-Preds: predicting compound–protein interactions based on drug chemical structure and protein sequences. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 10(5), 1224-1233.
7) Gottlieb, A., Stein, G. Y., Ruppin, E., & Sharan, R. (2011). Predict: a method for inferring novel drug indications with application to personalized medicine. Molecular Systems Biology, 7(1), 496.
8) S. Khaleelullah, P. Marry, P. Naresh, P. Srilatha, G. Sirisha and C. Nagesh, "A Framework for Design and Development of Message sharing using Open-Source Software," 2023 International Conference on Sustainable Computing and Data Communication Systems (ICSCDS), Erode, India, 2023, pp. 639-646, doi: 10.1109/ICSCDS56580.2023.10104679.
9) Cami, A., Manzi, S., Arnold, A., Reis, B., & Denny, J. (2014). Predicting adverse drug events using publicly available PubChem data. Clinical Pharmacology & Therapeutics, 95(5), 586-593.
10) Guo, L., & Zhu, Y. (2012). Toward the prediction of drug adverse effects by the chemical–chemical interactions. Journal of Chemical Information and Modeling, 52(12), 2840-2847.
11) Huang, L., Li, F., Sheng, J., & Xia, X. (2013). Prediction of adverse drug reactions using decision tree modeling. Clinical Pharmacology & Therapeutics, 93(4), 408-415.
12) Naresh, P., & Suguna, R. (2019). Association Rule Mining Algorithms on Large and Small Datasets: A Comparative Study. 2019 International Conference on Intelligent Computing and Control Systems (ICCS). DOI:10.1109/iccs45141.2019.9065836.
13) Tatonetti, N. P., Ye, P. P., Daneshjou, R., & Altman, R. B. (2012). Data-driven prediction of drug effects and interactions. Science translational medicine, 4(125), 125ra31-125ra31.
14) Vilar, S., Harpaz, R., Uriarte, E., Santana, L., & Rabadan, R. (2013). Drug–drug interaction through molecular structure similarity analysis. Journal of the American Medical Informatics Association, 20(5), 796-803.

15) Saha, A., & Prasad, P. (2015). Analyzing protein sequence–structure–function relationships using supervised self-organizing maps. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 12(2), 476-487.
16) P. Naresh, K. Pavan kumar, and D. K. Shareef, 'Implementation of Secure Ranked Keyword Search by Using RSSE,' International Journal of Engineering Research & Technology (IJERT) ISSN: 2278-0181 Vol. 2 Issue 3, March – 2013.
17) M. I. Thariq Hussan, D. Saidulu, P. T. Anitha, A. Manikandan and P. Naresh (2022), Object Detection and Recognition in Real Time Using Deep Learning for Visually Impaired People. IJEER 10(2), 80-86. DOI: 10.37391/IJEER.100205.
18) Suguna Ramadass and Shyamala Devi 2019 Prediction of Customer Attrition using Feature Extraction Techniques and its Performance Assessment through dissimilar Classifiers Springer's book series Learning and Analytics in Intelligent Systems, Springer.
19) Segura-Bedmar, I., & Martínez, P. (2015). Relationship extraction: from text to knowledge. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery, 5(3), 157-171.
20) Ye, H., Liu, Q., Wei, J., & Construction, A. S. (2014). A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS ONE, 9(5), e94107.
21) Luo, H., Ye, H., & Ng, H. W. (2014). Computational methods for predicting drug–target interactions: a review. Combinatorial chemistry & high throughput screening, 17(5), 427-435.
22) Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., ... & Urban, L. (2012). Large-scale prediction and testing of drug activity on side-effect targets. Nature, 486(7403), 361-367.
23) Cheng, F., Yu, Y., Shen, J., Yang, L., Li, W., & Liu, G. (2011). Classification of cytochrome P450 inhibitors and noninhibitors using combined classifiers. Journal of chemical information and modeling, 51(5), 996-1011.
24) T. Aruna, P. Naresh, A. Rajeshwari, M. I. T. Hussan and K. G. Guptha, "Visualization and Prediction of Rainfall Using Deep Learning and Machine Learning Techniques," 2022 2nd International Conference on Technological Advancements in Computational Sciences (ICTACS), Tashkent, Uzbekistan, 2022, pp. 910-914, doi: 10.1109/ICTACS56270.2022.9988553.
25) V. Krishna, Y. D. Solomon Raju, C. V. Raghavendran, P. Naresh and A. Rajesh, "Identification of Nutritional Deficiencies in Crops Using Machine Learning and Image Processing Techniques," 2022 3rd International Conference on Intelligent Engineering and Management (ICIEM), London, United Kingdom, 2022, pp. 925-929, doi: 10.1109/ICIEM54221.2022.9853072.
26) Sanseau, P., Agarwal, P., Barnes, M. R., Pastinen, T., & Richards, J. B. (2012). Cardiometabolic sNPCGs for drugs and diagnostics. Drug discovery today, 17(15-16), 850-858.
27) B. Narsimha, Ch V Raghavendran, Pannangi Rajyalakshmi, G Kasi Reddy, M. Bhargavi and P. Naresh (2022), Cyber Defense in the Age of Artificial Intelligence and Machine Learning for Financial Fraud Detection Application. IJEER 10(2), 87-92. DOI: 10.37391/IJEER.100206.
28) Gottlieb, A., Stein, G. Y., Oron, Y., Ruppin, E., & Sharan, R. (2011). INDI: a computational framework for inferring drug interactions and their associated recommendations. Molecular Systems Biology, 7(1), 1-8.
29) Cheng, F., & Zhao, Z. (2012). Machine learning-based prediction of drug–drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. Journal of the American Medical Informatics Association, 19(e1), e278-e287.
30) Hussan, M.I. & Reddy, G. & Anitha, P. & Kanagaraj, A. & Pannangi, Naresh. (2023). DDoS attack detection in IoT environment using optimized Elman recurrent neural networks based on chaotic bacterial colony optimization. Cluster Computing. 1-22. 10.1007/s10586-023-04187-4.
31) P. Naresh, P. Srinath, K. Akshit, M. S. S. Raju and P. VenkataTeja, "Decoding Network Anomalies using Supervised Machine Learning and Deep Learning Approaches," 2023 2nd International Conference on Automation, Computing and Renewable Systems (ICACRS), Pudukkottai, India, 2023, pp. 1598-1603, doi: 10.1109/ICACRS58579.2023.10404866.
32) Cheng, F., Yu, H., & Xie, J. (2013). Rational use of drug–polypharmacology for drug repositioning. Drug discovery today: Therapeutic strategies, 10(3), e153-e160.
33) Yao, L., Rzhetsky, A., & Sun, F. (2015). Quantitative systems-level determinants of human genes targeted by successful drugs. Genome research, 25(6), 855-863.